Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Roivant SciencesROIV +0.77%51 Cash-to-Debt is 35.86 as of Jun. 2026, which is 223% above its 10-year median of 11.10. GuruFocus rates ROIV with a GF Score™ of 51/100 and a GF Value™ of $6.50 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 1,342 Biotechnology companies, Roivant Sciences ranks better than 67.66% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Roivant Sciences's cash to debt ratio for the quarter that ended in Jun. 2026 was 35.86.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Roivant Sciencescould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Roivant Sciences's Cash-to-Debt or its related term are showing as below:
ROIV'
s Cash-to-Debt Range Over the Past 10 Years
Min: 2.83 Med: 11.1 Max: 120.31
Current: 35.86
During the past 6 years, Roivant Sciences's highest Cash to Debt Ratio was 120.31. The lowest was 2.83. And the median was 11.10.
ROIV's Cash-to-Debt is ranked better than 67.66% of 1342
companies
in the Biotechnology industry
Industry Median: 7.39
vs ROIV: 35.86
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Roivant Sciences Cash-to-Debt Related Terms
Roivant Sciences Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Roivant Sciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Roivant Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Roivant Sciences Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Roivant Sciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Roivant Sciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Roivant Sciences (ROIV) has a Cash-to-Debt of 35.86 as of Jun. 2026. This is 223% above median its historical median of 11.10. Over the past decade, Roivant Sciences' Cash-to-Debt has ranged from 2.83 to 120.31. According to the industry distribution chart, Roivant Sciences ranks #434 out of 1342 companies in the Biotechnology industry, placing it in the top 32.3%.
Is Roivant Sciences' Cash-to-Debt too high?
Roivant Sciences' current Cash-to-Debt of 35.86 is 223% above median its 10-year median of 11.10. Over the past 10 years, this metric has ranged from a low of 2.83 to a high of 120.31. The Biotechnology industry median Cash-to-Debt is 7.39. Roivant Sciences' value of 35.86 is 385.3% above this industry median. Based on the distribution chart, Roivant Sciences ranks #434 out of 1342 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Roivant Sciences has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Cash-to-Debt compare to RPRX and INCY?
According to the Biotechnology industry distribution chart, Roivant Sciences ranks #434 out of 1342 companies for Cash-to-Debt. This puts Roivant Sciences in the upper half of its industry. The industry median Cash-to-Debt is 7.39. Roivant Sciences' value of 35.86 is 385.3% above this benchmark. Historically, Roivant Sciences' own Cash-to-Debt has ranged from 2.83 to 120.31 over the past decade. While the company's 10-year median is 11.10 vs. the industry median of 7.39, Roivant Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.39, based on 1,342 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Roivant Sciences's current Cash-to-Debt of 35.86 is 385.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Roivant Sciences's current Cash-to-Debt is 35.86, which is 223% above median its own 10-year median of 11.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (ROIV) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.50, compared to a current price of $36.75 — trading 465.4% above its estimated fair value. The current Cash-to-Debt is 35.86, which is 223% above median its 10-year median of 11.10 and 385.3% above the Biotechnology industry median of 7.39. Roivant Sciences' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Roivant Sciences (ROIV), the current Cash-to-Debt is 35.86 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Roivant Sciences (ROIV) Overvalued in 2026?
Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued.
The current stock price of $36.75 is trading 465.4% above its estimated GF Value™ of $6.50.
GuruFocus considers Roivant Sciences to be Significantly Overvalued.
Key valuation signals for ROIV:
Cash-to-Debt: 35.86 (223% above median its 10-year median of 11.10)
GF Value™: $6.50 vs. price of $36.75 (465.4% above fair value)
Industry Position: 385.3% above the Biotechnology median (#434 of 1342)
No single metric tells the full story. See the ROIV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
51GF Score
Get the complete analysis for ROIV
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROIV has been successfully added to your 
